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It has always been something of a mystery as to why different diseases of the basal 
ganglia may produce completely opposite effects on movement. Thus, defective 
dopaminergic inhibitory input into the striatum in Parkinson’s disease causes an 
akinetic-rigid syndrome, while destruction of the striatum in Huntington’s disease 
usually causes chorea. This theoretic paradox may be resolved by more detailed 
examination of the exact sites of striatal damage in the two opposing conditions (1). 
C. D. Marsden 
The complexity of the internal organization of the basal ganglia and its connections 
with other brain regions makes it difficult to understand the basal ganglia’s role in con- 
trolling normal motor movement and the pathophysiology of motor disorders. Never- 
theless, it is useful to attempt to find underlying principles of organization in the basal 
ganglia that can be used to make testable hypotheses about basal ganglia function. In 
the past several years, considerable new information has been learned about the neuro- 
chemical anatomy of the internal organization of the striatum and its projections. It is 
necessary to incorporate this new information in any new hypothesis about basal gan- 
glia function. 
Any coherent hypothesis concerning basal ganglia function must provide tentative 
explanations for a variety of abnormal movements. In general, the symptoms of basal 
ganglia disorders can be described as either hypokinetic or hyperhetic. Parkinson’s 
disease is the prototype hypokinetic syndrome, characterized by bradyhesia, rigidity, 
tremor, loss of postural reflexes, and occasionally, dystonia (1,2). Huntington’s dis- 
ease is the classic hyperkinetic syndrome, characterized by chorea, abnormal eye move 
ments, slowed and irregular line motor coordination, and in advanced cases, dystonia 
and rigidity (3,4). Other less common disorders, such as Wilson% disease, Hallervor- 
den-Spatz disease, and dystonia musculonun deformam, have combinations of the vari- 
ous h m  and hyperkinetic syndromes. All of these disorders result in striatal d y s h c -  
tion and yet can manifest quite disparate abnormalities in movement. In this article we 
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wil l  first describe the anatomy of the basal ganglia and then attempt to describe the 
pathophysiology of the movement disorders within the framework of our current know- 
ledge of basal ganglia anatomy and physiology. 
CLASSIC ANATOMY 
Dew of the connections of the basal ganglia have been reviewed elsewhere (5-8). 
Briefly, the major input to the basal ganglia comes from the cerebral cortex, and the 
neurotransmitter of this pathway is probably glutamic acid (9-1 1). All areas of cortex 
send somatotopically organized excitatory projections to the neostriatum (the olfactory 
tubercle, the nucleus accumbens, the caudate nucleus, and the putamen). The neostri- 
atum also receives inputs from the intralaminar nuclei of the thalamus, the substantia 
nigra pars compacta, the ventral tegmental area, and the raphe nuclei. The dorsal part 
of the caudate nucleus and the putamen appear to be the most important in the patho- 
physiology of movement disorders. 
Internally, the neostriatum consists largely of medium- to small-sized neurons with 
spiny dendrites (medium spiny neurons), whichuse gamma-aminobutyric acid (GABA) 
as their neurotransmitter ( 12,13). Many of these neurons appear to use one or more of a 
number of peptide neurotransmitters as well as GABA (8). The relationship of these 
peptides to Werent classes of medium spiny neurons will be discussed below. The me- 
dium spiny neurons are projection neurons and have a large number of recurrent axon 
collaterals that are distributed primarily within the cell’s dendritic field ( 14-1 6). In ad- 
dition to the medium spiny neurons, there are also small numbers of large cholinergic 
interneurons (large aspiny neurons) ( 17) and small somatostatin/neuropeptide Y hter- 
neurons (small aspiny neurons) (18-20). 
The neostriatal projection areas include the lateral globus pallidus (LGP), the medial 
globus pallidus (MGP), the substantia nigra pars reticulata (SNr), and the ventral pal- 
lidum(5,6,21). AbnomalfunctionsoftheLGP,MGP,and SNrappeartobeimportant 
in the pathogenesis of the movement disorders (22). These areas receive most of the out- 
put from caudate and putamen. Most of the neurons in LGP, MGP, and SNr are large 
projection neurons, and interneurons are infrequent. All pallidal cells appear to use 
GABA as an inhibitory neurotransmitter and do not appear to contain other neuro- 
transmitter peptides (22-24). 
The LGP sends projections to the subthalamic nucleus (5,6), which also receives a 
direct excitatory (presumably glutamatergic) projection from the motor cortex (25). 
The subthalamic nucleus sends a reciprocal projection back to LGP and additional p m  
jections to the MGP and SNr (5,6). The MGP and SNr, in turn, send their major inhi- 
bitory GABAergic projections to the ventral tier nuclei of the thalamus (5,6).. Both 
MGP and SNr send minor projections to the intralaminar thalamic nuclei and to the 
nucleus tegmenti pedunculopontis of the brainstem (5,6). The SNr’s major projection 
goes to the “ventromedial” nucleus of thalamus, which in turn projects to the entire 
frontal lobe in rat (26). In primates, the projection goes to magnocellular portions ofthe 
ventral anterior and dorsal medial thalamic nuclei, which then project onto prefrontal 
cortex, with some projections going to premotor and supplementary motor cortex (27). 
The MPG sends its mqjor projection to the pars oralis of the ventral lateral thalamic 
nucleus. Pars oralis in turn sends its projection to the supplementary motor cortex (28). 
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This thalamic projection is excitatory on cortical cells (29), and its neurotransmitter 
may be glutamate (30). 
Additional projections of the SNr are to the superior colliculus, the reticular forma- 
tion, the nucleus tegmenti pedunculopontis, and the substantia nigra pars compacta (5 ,  
6). The projection to the superior colliculus is important to the generation of normal 
eye movements (3 1 ). Finally, the substantia lligra pars compacta (SNc) consists of the 
dopamine cells that degenerate in Parkinson’s disease. These neurons send a dense 
dopaminergic projection to the entire neostriatum (32,33). 
THE ORIGINAL HYPOTHESIS 
Based on these anatomical data, we have previously proposed a model for the func- 
tional anatomy of the movement disorders (21). This hypothesis was based on the idea 
that normal motor behaviors or motor programs are reinforced via the basal ganglia by a 
corti~triato-pallido-thalam~rtical feedback loop. In conjunction with this rein- 
forcing loop, there is a rich series of interconnections between striatal GABAergic neu- 
rons, which reciprocally inhibit each other and thereby inhibit inappropriate motor 
movements. Within this scheme, the reinforcing feedback loop depends on excitatory 
cortical input to striatum, and then two sequential GABAergic inhibitory connections 
from striaturn to pallidum and from pallidum to thalamus, and then a final excitatory 
pathway from thalamus to cortex. Thus, when cortex is activated, there is disinhibi- 
tion (34-36) of the thalamocortical pathway, which reinforces the ongoing motor 
behavior. We hypothesized that in Parkinson’s disease, there was a loss of inhibitory 
dopaminergic input to striatum that resulted in excessive activation of the reinforcing 
feedback for my particular motor behavior and consequent inability to initiate new 
motor behaviors. In contrast, in Huntington’s disease, the neuronal loss in the stria- 
itself would impair the reinforcing feedback loop and make it dBicult to maintain a 
given motor behavior, while also impairing the inhibition of unwanted activities. This 
scheme was also consistent with the neuropharmacology of basal ganglia disorders 
This model, however, had a number of shortcomings. It led to the prediction that 
after striatal lesions, such as those seen in Huntington’s disease, there should be an u p  
regulation of GABA receptors in all the striatal projection areas (LGP, MGP, and 
SNr), whereas in contrast, in Parkinson’s disease, there should be down-regulation of 
GABA receptors in these same regions. Recent behavioral and neurochemical experi- 
ments have shown that this latter situation is not the case. In particular, after lesions of 
the nigrostriatal pathway, GABA receptors do appear to down-regulate locally in stri- 
atum and in LGP, but they upregulate in MGP and SNr (37). Behavioral and meta- 
bolic experiments on the effects of nigtostriatal lesions also dissociate the effects of the 
lesions on the LGP from those on the MGP and SNr (38-40). Overall, dopamine a p  
pears to be inhibitory on striatal outputs to LGP, but excitatory onto output to MGP 
and SNr (37). This differentiation between striatal outputs must be incorporated into 
any consistent model of basal ganglia function. 
A second dBkulty with the model is that it leads to the prediction that Parkhsonian 
patients should move faster, rather than slower, than normal. Such a prediction would 
be inconsistent with our current knowledge of the disorder (1). Third, in experimental 
(21). 
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animals, extensive striatal lesions do not elicit chorea in primates, cats, or rodents (41). 
Only lesions of the subthalamic nucleus can reliably cause choreifom movements in 
primates and humans (41). Recent anatomical evidence concerning the basal ganglia 
wil l  allow the incorporation of these features into a modified model of basal ganglia 
function. 
STRIATAL INHOMOGENEITIES 
Our original hypothesis was based on the concept that the striatum was a homoge- 
news structure and that striatal output neurons sent axon collaterals to the LGP, MGP, 
and SNr. Thus, differences in the function of different striatal regions were explained 
by the differences in their afferent projections from the cortex. In the past 10 years, it 
has become increasingly obvious that the internal organization of the striatum is far 
from homogeneous (7). 
In 1977 , Mensah described islands of increased cell density within the caudate puta- 
men (42). Apparently separate h m t h e  cell islands are inhomogeneities of acetylcho- 
linesterase ( AChE) staining, which have been demonstrated in fetal and dult sttiatum 
and are called “striosomes” or “patches” (43). During fetal mammalian developmmt, 
there are regions of intense AChE staining, termed striosomes, and lighter surrounding 
areas, termed matrix. This pattern is reversed in the adult, where the striosome is less 
intensely stained for AChE than the matrix. Subsequently, dense areas of dopamine 
terminals were observed in developing striatum that were called “dopamine islands” 
(44,45). The dopamine islands become less distinct near birth as dopamine terminals 
innervate the matrix. Studies have also demonstrated that in the fetus, the densely 
AChE-staining striosomes coincide with the dopamine islands (7,45). Interestingly, 
the cells destined to be part of the striosomes are born simultaneously during develop- 
ment, as evidenced by 3H-thymidine studies; the cells of the matrix are born later (46). 
The connections of cells in the striosomes differ from those in the matrix. The cells in 
the striosomes receive inputs from the dopamine cells in the medial part of the SNc (47, 
48). They project back primarily to the SNc, but not to the SNr (49,50). Other inputs 
to the striosomal neurons may come from medial frontal cortex, but not f h n  lateral 
prefrbntal, motor, or sensory cortex or from thalamus (5 1-5 5). The medial frontal cor- 
tical projection to the striosomes is from an area that also receives direct dopaminergic 
input from the ventral tegmental area (5 1). Striosomal neurons are primarily GABA- 
ergic, as are the matrix neurons, but the striosomes also have many neurons that stain 
intensively for substance P, dynorphin, and possibly, neurotensin (45,56,57). In adult- 
hood, the striosomes contain high concentrations of mu-opiate receptoxs in rodents and 
high concentrations of enkephalin and low levels of AChE staining in carnivores (55, 
58). The dendrites of the striosomal neurons appear to obey the boundaries of the strio- 
somes and do not cross into the matrix (59). 
The matrix neurons receive inputs from motor, sensory, supplementary motor, and 
association cortices, as well as from intralaminar nuclei of thalamus (7,5245). The 
cells of the matrix also receive dopaminergic input from the dopamine cells in the SNc 
and ventral tegmental area (VTA) (47,48). The level of dopaminergic input is probably 
lower in the matrix than in the striosomes (60). The neurons of the matrix are for the 
most part GABAergic and have projections to SNr, MGP, and LGP ( 12,13,6 1). Cells 
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that project to one area are unlikely to project to the other areas, and so the matrix itself 
has substantial inhomogeneities (6,15,62). 
An important feature of matrix inhomogeneity is the effect of dopamine on the neu- 
rons ofthe matrix. For many years, there has been controversy as to whether dopamine 
is excitatory or inhibitory onto striatal projections to LGP, MGP, and SNr (63). Some 
studies have suggested an excitatory effect and others an inhibitory effect, but few stu- 
dies have measured the effects of dopamine on striatal projections to d these areas si- 
multaneously. Those studies that have made these measurements actually suggest that 
the ultimate effect ofdopamine on striatal output to MGP and SNr is excitatory, where- 
as dopamine’s effects on striatal projections to LGP are inhibitory (3740). 
These differential effects of dopamine on striatal projections have important implica- 
tions for basal ganglia disorders, as they suggest that the loss of dopamine cells in Par- 
kinson’s disease removes excitatory influences on cells projecting to MGP and SNr, 
thereby reducing the GABAergic striatal inhibition of MGP and SNr cells. In addition, 
the inhibitory effects of dopamine on striatal neurons projecting to LGP are lost, there- 
by increasing striatal GABAergic inhibition of LGP. In Huntington’s disease, the loss 
of striatal neurons will result in some similarities to and some differences from Parkin- 
son’s disease. The similarity would be the reduced GABAergic inhibition of MGP and 
SNr neurons and the difference would be a loss of GAEiAergic striatal inhibition of 
LGP neurons. Clinically, Parkinson’s disease patients differ from Huntington’s dis- 
ease patients in that the former manifest rigidity and tremor, whereas the latter have 
chorea. The two diseases are similar in that in both, the patients have bradykinesia and 
bradyphrenia. 
Interestingly, recent studies have indicated that groups of neurons are selectively 
spared in the striatum of Hungtington’s disease patients (64,65). It is possible that the 
selective sparing is due to the preferential vulnerability of one or the other group of stri- 
atal output neurons. In future studies, it will be important to define which output neu-: 
rons die earliest in the disease. 
Communication between striosomal neurons and matrix neurons has not been dem- 
onstrated directly, although the large cholinergic aspiny neurons of striatum do not a p  
pear to obey the borders of the striosome or matrix (C. J. Wilson, personal communica- 
tion). Biochemically and behaviorally, however, dopamine appears to have inhibitory 
inputs on cholinergic neurons, which in turn appear to be excitatory on GABAergic 
striatal projection neurons (8,66,67). Because dopamine appears to inhibit choliier- 
gic neurons, it is most likely that, functionally, cholinergic effects on striatal projections 
to LGP predominate. The existence of this possible interconnection could be deter- 
mined experimentally, using studies combining immunobistochemical stains for ace- 
tylcholine neurons and retrograde tracing of striato-lateral pallidal cells. 
An additional level of complexity to the striatal organization is provided by the pres- 
ence of peptides within GABAergic striatal neurons. It now appears that a great many 
of the GABAergic medium spiny neurons also contain a peptide (eitper substance P, 
enkephalin, neurotensin, or dynorphin) (68-70). The somatostatin neurons (which 
also contain neuropeptide Y) appear to be interneurons that are largely confined tathe 
matrix (50). The dynorphin and, possibly, neurotensin neurons appear to be largely 
located in the striosomes (56,5 7). The enkephalin neurons appear to be largely located 
in the matrix (6,56). The localization of substance P neurons is less certain, with some 
Movement Duoniem, VoL I .  No. 1. 1986 
8 J. B. PENNEYANDA. B. YOUNG 
studies suggesting they are largely in striosomes and others suggesting they are largely 
in matrix (56,58,69). There is less confusion about the distriition of the peptides in 
striatal efferent projections (6). The enkephalin neurons project largely to the LGP 
(71-73). The substance Pneurons projectlargelytotheMGP and SNr (73,74),whme- 
as the dynorpbin neurons project largely to the SNr (75,76). The neurotensin neurons 
may project to SNc (77). The significance of the neuropeptides in the various striatal 
projection neurons is currently unknown, but presumably they could function either as 
modifjers of GABA’s effects, as trophic factors, or as neuromodulators in their own 
right. 
In our initial hypothesis, we predicted that the cells of the subthalamic nucleus would 
be inhibitory on cells of the medial globus pallidus. Recent evidence suggests that the 
cells of the subthalamic nucleus are excitatory and that they may drive the cells of the 
medial globus pallidus and substantia nigra pars reticulata (78). They may even use 
glutamic acid as a neurotransmitter (A. J .  Beik, personal communication). 
REVISED HYPOTHESIS 
The recent biochemical, anatomical, and electrophysiological studies concerningthe 
inhomogeneities of the striatal system provide a new hamework in which to interpret 
the pathophysiology of movement disorders. In the new scheme (Fig. 1 ), motor behavi- 
ors would still be maintained under normal conditions by a reinforcing feedback loop 
horn cortex through basal ganglia to thalamus and back to cortex, as previously hypo- 
thesized (21). The input from motor cortex would synapse on matrix neurons which 
projectto MGP and/or to SNr, and these striatal cells in turn would be inhibitory on the 
MGP and SNr cells projecting to the thalamus. These latter projections would be in- 
hibitory onto thalamomrtical neurons. Additional cortical inputs would excite the stri- 
atal matrix neurons which project to and inhiiit LGP. The cortical inputs to these 
matrix neurons would be those important in regulating,the suppression of unwanted 
motor behaviors, whereas the cortical inputs to neurons projecting to MGP and SNr 
would be involved in promoting a particular motor behavior (Fig. 2). The inhibition of 
LGP would result in disinhiiion of subthalamic nucleus, which would in turn drive or 
excite those MGP and SNr neurons that would suppress unwanted movements. In ad- 
dition to these rather simple feedback loops, rich axonal collaterals between striatal 
neurons would provide communication between striatal neurons for more sophisticated 
refinement of acquired motor programs. 
According to this scheme, the primary feedback loop reinforcing a particular motor 
behavior would be impaired in both Parkinson’s and Huntington’s diseases. In Parkin- 
son’s disease, there would be a loss of excitatory dopaminergic input to striatal cells 
projecting to MGP and SNr. In Huntington’s disease, the striatal neurons themselves 
would be damaged, thus interrupting the circuit. The result ofthis damage in both cases 
would be a slowness and poverty of movement. The distinguishing feature between 
Parkinson’s disease and Huntington’s disease would rest in alteration of the striatd 
projections to LGP. In Parkinson’s disease, inhibitory dopaminergic input to striatal 
neurons projectingto LGP would be lost. Thus, there would be decreased activity (Le., 
increased inhibition) of LGP neurons, which would result in disinhibition of subtha- 
l d c  nucleus input to MGP and SNr, reinforcing inhibition of unwanted movements. 
If this suppression is excessive, then it would be dif€icult to switch to new behaviors in 
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FIG. 1. Schematic diagram of the connections of the basal ganglia Connections are indicated by the ar- 
rows. In large letters are the brain regions areas and in smaller letters are the putative neurotransmitters ofthe 
pathways. Abbreviations: MFC, medial prefrontal cortex; PFC, prefrontal cortex; SMA, supplementary 
motor area; PMC, premotor cortex; MC, motor cortex; SC, sensory and parietal cortex; STRI, striosomes in 
stria-, VL, ventral lateral thalamus; VA, ventral anterior thalamus; LGP, lateral globus pallidus; MGP, 
medial globus pallidus; SNr, substantia nigapars reticdata; VTA, ventral tegmental area; SNc, substantia 
nigra pars compacta; STN, subthalamic nucleus; GLU, glutamic acid or glutamate-like substance; GAEA, 
gamma-aminobutyric acid; NT, neurotmsin; ENK, leucine-enkephalin, SUB P, substance P; DYN, dynor- 
phh; DA, dopamine. 
the context of additional difficulty in maintaining the ongoing behavior. Thus, the par- 
kinsonian patient would have slowness and poverty of movement and difficulty switch- 
ing to new motor programs. The gradual decrescendo pattern seen in parkinsonians’ 
attempts to maintain motor behaviors (1,79) may be the result of excess negative input 
to the striatal cells that project to MGP and SNr from collaterals of the overactive stri- 
atal cells that project to LGP. 
In Huntington’s disease, we would hypothesize that there is first a loss of matrix neu- 
rons projecting to LGP. This loss would result in disinhibition of the LGP and subse 
quent excessive inhiiition of subthalamic nucleus. As the subthalamic nucleus would 
normally drive the MGP and SNr cells that suppress abnormal movements, this sup 
pression would now be impaired and unwanted movements would be expressed ran- 
domly. Excess inhibition of subthalamic nucleus in Hungtington’s disease would pro- 
vide a tentative explanation for the failure of investigators to produce involuntary 
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PIG. 2. Schematic diagram of reinforcing and suppressing feedback loops for motor programs in normal in- 
dividuals, Parkinson’s disease patients and Huntington’s disease patients. The loops are drawn for a h m  
thetical ‘‘motor program” for grasp (G). While maintaining a grasp, release (R) programs would normally be 
suppressed (or not reinforced). The open neurons are excitatory, and the closed ones are inhibitory. Under 
normal circumstances, when the grasp movement is initiated andsustained, the pathway from cortex through 
striatum (STR), medial globus pallidus (MGP), and thalamus (T) is reinforced for grasp. (The thickness of 
the lines indicates relative activiv in the various pathways.) The pathway for suppression ofunwanted move- 
ments g a s  through STR. lateral globus pallidus (LGP), subthalamic nucleus (STN), MGP, and T back to 
cortex. In Parkinson’s disease both excitatory dopamine input from substantia nigra pars compacts( SNc) to 
the reinforcingloop is lost (resultingin impaired reinforcement of grasp) as well as inhibitory input to the sup- 
pressing loop (enhancing the suppression of unwanted movements). In Huntington’s disease, striatal neu- 
rons degenerate (with relative sparing of striosomal neurons-closed circle with white S). and the reinforcing 
loop is impaired, as is the suppressing loop. This latter situation leads to poor maintenance of the ongoing 
grasp and relative excitation or dishhibition of unwanted movements (release). 
movements with striatal lesions in animals (41), as it would require a selective lesion of 
those cells projecting to LGP. The loss of subthalamic activity in Huntington’s disease 
would result in a decreased ability to suppress unwanted movements in the face of dif- 
ficulty in maintaining ongoing movements. Thus, patients would have slowness of vol- 
untary movement and chorea. Later in the disease, striosomal neurons would also be- 
come damaged, and at this point, symptoms of rigidity and dystonia may appear. This 
scheme could be tested by examination of early Huntington’s cases in which a subset of 
matrix neurons projecting to lateral globus pallidus would predictably be affected first. 
There is some evidence for this hypothesis from the prominent enkephalin loss in Hun- 
tington’s disease while neurotensin is preserved (80,81). Furthermore, younger pa- 
tients with Hungtinton’s disease have more prominent parkimonian symptoms (I. 
Shoulson, personal communication), and pathologically, these early patients have 
more severe neuronal loss (82). 
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This interpretation of basal ganglia circuitry would provide a tentative explanation 
for the physiologic chorea seen in newborn infants (83). At approximately 2-6 months 
postnatally, human infants display choreic movements. Striosomal neurons make their 
connections before matrix neurons (84). We have observed intense patches of AChE 
staining in a 6-week-old human brain (unpublished observations), which were similar 
to those seen in prenatal cats before the matrix develops (45). Between 2 and 6 months 
postnatally, therefore, there may be a paucity of neurons that would mediate both the 
maintenance of motor behavior and suppression of unwantedmovements. The late de- 
velopment of these matrix neuron connections may be part of the reason why the move- 
ment disorders seen often after perinatal asphyxia are delayed in onset. The movement 
disorders associated with perinatal asphyxia may be characterized by a mix of abnor- 
malities, such as chorea, dystonia, rigidity, or spasticity. Perhaps each particular 
movement disorder depends on the developmental stage of the striatal neuronal sub- 
types at the time of injury. Such apossibility can be tested experimentally by analyzing 
whether or not specific populations of matrix neurons have degenerated in cases of neo- 
natal asphyxia. 
IMPLICATIONS FOR NEUROPHARMACOLOGY 
The neuropharmacology of movement disorders st i l l  fits very consistently into the 
new scheme. In Parkinson’s disease, dopaminergic input is lost and must be replaced 
with either precursers for dopamine or dopamine agonists. As dopamine has inhibitory 
effects on excitatory cholinergic interneurons within striatum (85,86), anticholinergic 
medications would also be expected to be helpful (87). Within the model, the choliner- 
gic interneurons would be predicted to influence primarily those striatal neurons that 
project to LGP and not those projecting to MGP and SNr. At the current time, infor- 
mation concerning the cholinergic connections is st i l l  rudimentary, and the connections 
between the striosomal and matrix neurons are still unknown. 
Although it is s t i l l  under investigation, dopamine receptors on striosomes and certain 
subsets of matrix neurons may differ from those on other matrix neurons. D1 receptors 
may be localized to specific sets of striatal neurons, and excitation of these receptors 
may result in different phannacologic effects than activation of Dz receptors. Prelim- 
inary evidence in rat striatum would suggest that D1 receptors are localized preferen- 
tially on striosomal neurons (88). Future studies of the differential effects of D1 and D2 
agonists and antagonists on movement disorders will help to refute or substantiate these 
possibilities. 
GABAergic manipulations in both Huntington’s and Parkinson’s diseases have been 
disappointing (89,90). The lack of effectiveness of these drugs may be due to the im- 
portance of spatial and temporal sequencing of signals between the GABAergic neu- 
rons during the regulation of normal motor movements. It is unlikely that replacement 
therapy would be helpful in alleviating abnormalities in such complex circuitry. The in- 
teresting clinical observation that opiate agonists suppress akathesia (9 1) would predict 
that this neuroleptic-induced side effect is mediated by striatd projections to LGP, as 
these neurons contain GAJ3A and enkephalins. 
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CONCLUSIONS 
Although this revised model of the functional anatomy of basal ganglia disorders is 
likely to be r&ted with time, it provides a framework in which to test specific predic- 
tions of basal ganglia function. With new techniques for looking at human brain func- 
tion and pharmacology in vim it may be possible to test some predictions directly. Also, 
more intense and sophisticated analyses of postmortem material h m  vaxious basal 
ganglia disorders would be helpful in defining the selective vulnerability of specific stri- 
atal subsets of neurons. The future will undoubtedly provide interesting new twists and 
complexities to incorporate into our understanding of the pathophysiology of move- 
ment disorders. 
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